Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 3 | 2025 | 104 | 1.160 |
Why?
|
| Thrombosis | 3 | 2024 | 206 | 0.970 |
Why?
|
| Hemorrhage | 3 | 2024 | 285 | 0.900 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2021 | 50 | 0.830 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 45 | 0.800 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 67 | 0.780 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 113 | 0.770 |
Why?
|
| Rituximab | 2 | 2023 | 89 | 0.740 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 32 | 0.560 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 46 | 0.540 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 369 | 0.540 |
Why?
|
| Medical Marijuana | 2 | 2025 | 8 | 0.410 |
Why?
|
| Graft vs Host Disease | 2 | 2025 | 113 | 0.400 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2025 | 191 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2025 | 352 | 0.350 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 250 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 184 | 0.270 |
Why?
|
| Cyclophosphamide | 2 | 2025 | 84 | 0.260 |
Why?
|
| Medical Oncology | 2 | 2025 | 69 | 0.250 |
Why?
|
| Aged | 12 | 2025 | 14958 | 0.250 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 25 | 0.230 |
Why?
|
| Humans | 21 | 2025 | 65124 | 0.230 |
Why?
|
| Lupus Nephritis | 1 | 2025 | 37 | 0.230 |
Why?
|
| Female | 14 | 2025 | 34016 | 0.210 |
Why?
|
| Hemostasis | 1 | 2024 | 19 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2023 | 8 | 0.210 |
Why?
|
| Vincristine | 1 | 2023 | 26 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2025 | 93 | 0.210 |
Why?
|
| Mutation | 2 | 2025 | 2658 | 0.200 |
Why?
|
| Prednisone | 1 | 2023 | 83 | 0.200 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 182 | 0.200 |
Why?
|
| Doxorubicin | 1 | 2023 | 98 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 704 | 0.190 |
Why?
|
| Male | 13 | 2025 | 31042 | 0.190 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 402 | 0.180 |
Why?
|
| Hematology | 1 | 2022 | 11 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2024 | 525 | 0.180 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 235 | 0.180 |
Why?
|
| Quarantine | 1 | 2021 | 12 | 0.170 |
Why?
|
| Curriculum | 1 | 2025 | 608 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 373 | 0.160 |
Why?
|
| Neoplasms | 2 | 2021 | 1367 | 0.160 |
Why?
|
| Chordoma | 1 | 2020 | 5 | 0.160 |
Why?
|
| Infection Control | 1 | 2021 | 104 | 0.160 |
Why?
|
| Immunotherapy | 2 | 2020 | 274 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 464 | 0.150 |
Why?
|
| Spinal Neoplasms | 1 | 2020 | 16 | 0.150 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5788 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 804 | 0.150 |
Why?
|
| Hepatitis | 1 | 2019 | 58 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 219 | 0.130 |
Why?
|
| Middle Aged | 6 | 2025 | 18267 | 0.130 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 173 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2024 | 2102 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2020 | 519 | 0.120 |
Why?
|
| Melanoma | 1 | 2020 | 333 | 0.120 |
Why?
|
| Risk Factors | 2 | 2024 | 5429 | 0.120 |
Why?
|
| Adult | 5 | 2025 | 17356 | 0.120 |
Why?
|
| Urothelium | 1 | 2015 | 22 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 1222 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 108 | 0.100 |
Why?
|
| Prognosis | 3 | 2025 | 1785 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 142 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 5612 | 0.090 |
Why?
|
| Survival Rate | 2 | 2025 | 844 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1006 | 0.080 |
Why?
|
| Young Adult | 3 | 2025 | 4810 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2023 | 2619 | 0.060 |
Why?
|
| Symptom Flare Up | 1 | 2025 | 15 | 0.060 |
Why?
|
| Methylprednisolone | 1 | 2025 | 37 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2025 | 250 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2023 | 6862 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 644 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 183 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2025 | 380 | 0.050 |
Why?
|
| Clone Cells | 1 | 2023 | 111 | 0.050 |
Why?
|
| Abatacept | 1 | 2023 | 67 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 312 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 55 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 587 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 281 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 105 | 0.040 |
Why?
|
| Pleural Neoplasms | 1 | 2021 | 19 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 90 | 0.040 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 52 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 72 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 1 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 222 | 0.040 |
Why?
|
| Imatinib Mesylate | 1 | 2020 | 34 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 742 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 60 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 121 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 374 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 372 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 348 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 166 | 0.030 |
Why?
|
| Palliative Care | 1 | 2021 | 249 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2019 | 127 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 309 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 196 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 114 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 318 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1119 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 142 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2763 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1418 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 675 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2483 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 3762 | 0.020 |
Why?
|
| Hospitalization | 1 | 2020 | 1392 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 991 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 2244 | 0.020 |
Why?
|
| United States | 1 | 2023 | 8097 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6305 | 0.020 |
Why?
|